Kim Chi, MD, Vice President & Chief Medical Officer of BC Cancer speaks about TITAN: A final analysis with close to four years of follow-up data evaluating Erleada versus placebo in patients with metastatic castration-sensitive prostate cancer receiving hormone therapy (Abstract #11).
Â
RARITAN, N.J. /PRNewswire/ — Janssen Pharmaceutical Inc., Feb. 2, 2021, Johnson & Johnson companies today reported that at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium with 12 data presentations, including three company-sponsored oral presentations from the clinical development program ERLEADA® (apalutamide), the depth of their solid tumor portfolio will be highlighted. The virtual meeting will be held from 11-13 February 2021.
Â
New ERLEADA® Analyses illustrate the extent of the current clinical research program
Â
Oral presentations will feature data from three Phase 3 registration clinical trials:
Â
ACIS: Review of the evaluation of ERLEADA® (apalutamide) in conjunction with ZYTIGA® (abiraterone acetate) plus prednisone versus abiraterone acetate plus prednisone in patients with prostate cancer immune to chemo-naive metastatic castration (Abstract #9)
Â
TITAN: Final study of patients with metastatic castration-sensitive prostate cancer (mCSPC) undergoing hormone therapy with close to four years of follow-up evidence assessing ERLEADA® versus placebo overall survival (OS) and other endpoints (Abstract #11)
Â
SPARTAN: Post-hoc analysis of data from a biomarker cohort study defining long-term response molecular signatures to ERLEADA® (Abstract #8)
Â
Combined, the ERLEADA® presentations contain evidence from more than 2,000 patients through various trials. In its approved indications of metastatic castration-sensitive prostate cancer (TITAN) and non-metastatic castration-resistant prostate cancer (SPARTAN), ERLEADA® showed a statistically significant improvement in OS.1 The safety profile of ERLEADA® is verified by both TITAN and SPARTAN trials, with over four years of patient follow-up showing exposure-adjusted Grade 3 and 4 adverse event rates.